Dexus (DEXSF) Research

Dexus stands as a prominent real estate powerhouse in Australia, overseeing an impressive $44.3 billion portfolio of high-quality Australian properties. Our fundamental belief is that robust client relationships are paramount to enduring success, driving our deep commitment to crafting engaging and inspiring environments for our customers. Operating exclusively within Australia, Dexus directly owns a substantial $16.5 billion in office and industrial assets. Furthermore, we manage an additional $15.6 billion in diverse property types—including office, retail, industrial, and healthcare sectors—on behalf of third-party clients. A significant development pipeline, valued at $11.4 billion, is strategically poised to expand both direct and managed portfolios, thereby enhancing future profitability. As Australia's preferred office partner, Dexus commands an extensive footprint of 1.6 million square metres of office space spread across 51 properties. Listed on the Australian Securities Exchange under the ticker DXS, Dexus ranks among the Top 50 entities by market capitalization, supported by a global investor base exceeding 29,000 individuals from 24 nations. Leveraging 36 years of deep expertise in property investment, development, and asset management, Dexus boasts a formidable record in capital and risk stewardship, consistently delivering exceptional service to tenants and superior risk-adjusted returns for its investors.

Market snapshot

Symbol
DEXSF
Price
$4.05
Day change
0.00%
Market cap
$6.2B
P/E ratio
13.23x
52-week range
3.525-5.13
Sector
Real Estate
Industry
REIT - Diversified
Next earnings
in 2 months

Peer companies

  • British Land Company Plc (BRLAF)
  • British Land Company Plc (BTLCY)
  • City Developments Limited (CDEVF)
  • Charter Hall Group (CTOUF)
  • Fibra UNO (FBASF)
  • The GPT Group (GPTGF)
  • Land Securities Group plc (LDSCY)
  • LondonMetric Property Plc (LNSPF)

Open Dexus (DEXSF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.